ZA915466B - A process for the preparation of an agent with the active substance flupirtine to combat muscular tension and the use of flupirtine for such purpose - Google Patents

A process for the preparation of an agent with the active substance flupirtine to combat muscular tension and the use of flupirtine for such purpose

Info

Publication number
ZA915466B
ZA915466B ZA915466A ZA915466A ZA915466B ZA 915466 B ZA915466 B ZA 915466B ZA 915466 A ZA915466 A ZA 915466A ZA 915466 A ZA915466 A ZA 915466A ZA 915466 B ZA915466 B ZA 915466B
Authority
ZA
South Africa
Prior art keywords
flupirtine
agent
preparation
active substance
muscular tension
Prior art date
Application number
ZA915466A
Other languages
English (en)
Inventor
Michael Lobisch
Lobisch Michael
Bernd Nickel
Nickel Bernd
Jurgen Engel
Engel Jurgen
Ralph Venhaus
Venhaus Ralph
Istvan Szelenyi
Szelenyi Istvan
Peter Emig
Emig Peter
Original Assignee
Asta Medica Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asta Medica Ag filed Critical Asta Medica Ag
Publication of ZA915466B publication Critical patent/ZA915466B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pyrrole Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Paints Or Removers (AREA)
  • Golf Clubs (AREA)
  • Details Of Television Scanning (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Plant Substances (AREA)
ZA915466A 1990-07-14 1991-07-12 A process for the preparation of an agent with the active substance flupirtine to combat muscular tension and the use of flupirtine for such purpose ZA915466B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4022442 1990-07-14
IN421CA1991 IN172468B (sk) 1990-07-14 1991-06-04

Publications (1)

Publication Number Publication Date
ZA915466B true ZA915466B (en) 1992-04-29

Family

ID=25895002

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA915466A ZA915466B (en) 1990-07-14 1991-07-12 A process for the preparation of an agent with the active substance flupirtine to combat muscular tension and the use of flupirtine for such purpose

Country Status (30)

Country Link
US (2) US5162346A (sk)
EP (2) EP0659410B1 (sk)
KR (1) KR0182811B1 (sk)
CN (1) CN1070700C (sk)
AT (2) ATE133564T1 (sk)
AU (1) AU634073B2 (sk)
CA (1) CA2046943C (sk)
CZ (1) CZ280879B6 (sk)
DE (3) DE59109222D1 (sk)
DK (2) DK0467164T3 (sk)
EG (1) EG19814A (sk)
ES (2) ES2164111T3 (sk)
GR (1) GR3019179T3 (sk)
HR (1) HRP920667B1 (sk)
HU (1) HU206973B (sk)
IE (1) IE74688B1 (sk)
IL (1) IL98810A (sk)
IN (1) IN172468B (sk)
LT (1) LT3593B (sk)
LV (1) LV10048B (sk)
MC (1) MC2272A1 (sk)
MX (1) MX9100160A (sk)
NO (1) NO912758L (sk)
NZ (1) NZ238940A (sk)
PT (1) PT98291B (sk)
RO (1) RO108220B1 (sk)
RU (1) RU2070408C1 (sk)
SI (1) SI9111227B (sk)
SK (1) SK279567B6 (sk)
ZA (1) ZA915466B (sk)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE160696T1 (de) * 1992-03-11 1997-12-15 Asta Medica Ag Tabletten, granulate und pellets mit hohem gehalt an wirkstoffen für hochkonzentrierte, feste darreichungsformen
DE4319649A1 (de) * 1993-03-18 1994-09-22 Asta Medica Ag Feste Flupirtin enthaltende orale Darreichungsformen mit kontrollierter Wirkstoffabgabe
DE4327516A1 (de) * 1993-08-17 1995-02-23 Asta Medica Ag Primäre und sekundäre neuroprotektive Wirkung bei neurodegenerativen Erkrankungen von Flupirtin
GB9426079D0 (en) * 1994-12-23 1995-02-22 Orion Yhtymae Oy A gelatine capsule
DE19541405A1 (de) * 1995-11-07 1997-05-15 Asta Medica Ag Verwendung von Flupirtin zur Prophylaxe und Therapie von Erkrankungen, die mit einer Beeinträchtigung des hämatopoetischen Zellsystems einhergehen
US6284794B1 (en) 1996-11-05 2001-09-04 Head Explorer Aps Method for treating tension-type headache with inhibitors of nitric oxide and nitric oxide synthase
US6610324B2 (en) * 1999-04-07 2003-08-26 The Mclean Hospital Corporation Flupirtine in the treatment of fibromyalgia and related conditions
JP2003530308A (ja) * 1999-08-03 2003-10-14 アーヴェーデー．ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディートゲゼルシャフト 犬および猫の退行性関節疾患に起因する痛みを軽減するためのフルピルチンの使用
US6821995B1 (en) 1999-12-01 2004-11-23 Duke University Method of treating batten disease
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
RU2213565C1 (ru) * 2002-06-24 2003-10-10 Общество с ограниченной ответственностью "Паркинфарм" Способ лечебного воздействия на организм пациента при лечении болезни паркинсона
DE10255415A1 (de) * 2002-11-28 2004-06-09 Bayer Healthcare Ag Dermale Applikation von Flupirtin
DE10327674A1 (de) * 2003-06-20 2005-01-05 Awd.Pharma Gmbh & Co. Kg Injizierbare Darreichungsform von Flupirtin
US20050089559A1 (en) * 2003-10-23 2005-04-28 Istvan Szelenyi Combinations of potassium channel openers and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
DE102004001558A1 (de) * 2004-01-10 2005-08-18 Bayer Healthcare Ag Arzneimittel zur topischen Applikation bei Tieren
US20050196461A1 (en) * 2004-01-14 2005-09-08 Udell Ronald G. Ceramide formulations suitable for oral administration
CA2554959A1 (en) * 2004-01-29 2005-08-11 Neuromolecular, Inc. Combination of a nmda receptor antagonist and a mao-inhibitor or a gadpf-inhibitor for the treatment of central nervous system-related conditions
US20050220862A1 (en) 2004-03-31 2005-10-06 Bernstein Joel E Compositions with reduced hepatotoxicity
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
EP1688141A1 (en) * 2005-01-31 2006-08-09 elbion AG The use of flupirtine for the treatment of overactive bladder and associated diseases, and for the treatment of irritable bowel syndrome
WO2006121560A2 (en) 2005-04-06 2006-11-16 Adamas Pharmaceuticals, Inc. Methods and compositions for treatment of cns disorders
US20090318507A2 (en) * 2006-05-02 2009-12-24 Chris Rundfeldt Potassium Channel Activators for the Prevention and Treatment of Dystonia and Dystonia Like Symptoms
US7960436B2 (en) * 2006-06-05 2011-06-14 Valeant Pharmaceuticals International Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
US8993593B2 (en) * 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
AU2007288253B2 (en) * 2006-08-23 2013-05-02 Xenon Pharmaceuticals Inc. Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
US8722929B2 (en) * 2006-10-10 2014-05-13 Valeant Pharmaceuticals International N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators
KR20090083479A (ko) * 2006-11-28 2009-08-03 밸리언트 파마슈티컬즈 인터내셔널 칼륨 채널 조절제로서의 1,4 디아미노 이환 레티가빈 유사체
US20080279930A1 (en) * 2007-05-07 2008-11-13 Bernd Terhaag Controlled-Release Flupirtine Compositions, Compacts, Kits and Methods of Making and Use Thereof
US8367684B2 (en) * 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
US20100256145A1 (en) * 2007-08-01 2010-10-07 H. Lundbeck A/S Use of kcnq potassium channel openers for reducing symptoms of or treating disorders or conditions wherein the dopaminergic system is disrupted
US8563566B2 (en) * 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
US7786146B2 (en) * 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
ES2347119B2 (es) * 2009-04-22 2011-04-28 Universidad De Santiago De Compostela Nanocapsulas de poliarginina.
DE102010030053A1 (de) 2010-06-14 2011-12-15 Awd.Pharma Gmbh & Co.Kg Injizierbare Darreichungsform von Flupirtin
JP6251667B2 (ja) * 2014-06-03 2017-12-20 アサヒカルピスウェルネス株式会社 錠剤型即放性製剤及びその製造方法
DE102017007385A1 (de) 2017-08-02 2019-02-07 Christoph Hoock Maleatfreie feste Arzneimittelformen

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1795858C2 (de) 1968-07-19 1979-01-11 Deutsche Gold- Und Silber-Scheideanstalt Vormals Roessler, 6000 Frankfurt Benzylaminopyridine
DE3133519A1 (de) 1980-09-13 1982-06-09 Degussa Ag, 6000 Frankfurt "2-amino-3-carbethoxyamino-6-(p-fluor-benzylamino)-pyridin-maleat"
EP0189788B1 (de) * 1985-01-23 1989-09-13 ASTA Pharma Aktiengesellschaft Synergistische Kombination von Flupirtin und nicht-steroidalen Antiphlogistika
DE3604575A1 (de) * 1985-02-23 1986-08-28 Degussa Ag, 6000 Frankfurt Kombination von flupirtin und anticholinergisch wirkenden spasmolytika
DE3663775D1 (en) * 1985-02-23 1989-07-13 Asta Pharma Ag Combination of flupirtin with spasmolytics having an anticholinergic effect
FI855016A (fi) * 1985-06-28 1986-12-29 Degussa Synergistisk kombination av flupirtin och 4-acetamido-fenol.

Also Published As

Publication number Publication date
PT98291A (pt) 1992-05-29
ATE206919T1 (de) 2001-11-15
EP0659410A3 (de) 1995-10-25
PT98291B (pt) 1999-01-29
LV10048B (en) 1995-06-20
KR920002147A (ko) 1992-02-28
EP0659410B1 (de) 2001-10-17
HRP920667B1 (en) 1998-06-30
AU634073B2 (en) 1993-02-11
NO912758D0 (no) 1991-07-12
LV10048A (lv) 1994-05-10
IN172468B (sk) 1993-08-14
ES2082887T3 (es) 1996-04-01
KR0182811B1 (ko) 1999-05-01
EP0467164A3 (en) 1992-04-15
DE59109222D1 (de) 2001-11-22
HUT59313A (en) 1992-05-28
EP0467164A2 (de) 1992-01-22
LT3593B (en) 1995-12-27
MC2272A1 (fr) 1993-06-23
NZ238940A (en) 1997-05-26
NO912758L (no) 1992-01-15
HU912359D0 (en) 1991-12-30
ATE133564T1 (de) 1996-02-15
SK279567B6 (sk) 1999-01-11
DE59107331D1 (de) 1996-03-14
CZ280879B6 (cs) 1996-04-17
HRP920667A2 (en) 1996-10-31
IE912451A1 (en) 1992-01-15
CN1070700C (zh) 2001-09-12
CA2046943A1 (en) 1992-01-15
DE4122166A1 (de) 1992-01-16
CS210191A3 (en) 1992-02-19
RO108220B1 (ro) 1994-03-31
SI9111227A (en) 1995-06-30
LTIP919A (en) 1995-03-27
EG19814A (en) 1996-02-29
CN1058716A (zh) 1992-02-19
GR3019179T3 (en) 1996-06-30
SI9111227B (sl) 2000-12-31
MX9100160A (es) 1992-02-28
EP0659410A2 (de) 1995-06-28
IL98810A0 (en) 1992-07-15
IE74688B1 (en) 1997-07-30
AU8040391A (en) 1992-01-16
DK0467164T3 (da) 1996-03-04
US5284861A (en) 1994-02-08
EP0467164B1 (de) 1996-01-31
IL98810A (en) 1996-01-19
CA2046943C (en) 1996-03-12
ES2164111T3 (es) 2002-02-16
DK0659410T3 (da) 2001-12-27
HU206973B (en) 1993-03-01
US5162346A (en) 1992-11-10
RU2070408C1 (ru) 1996-12-20

Similar Documents

Publication Publication Date Title
ZA915466B (en) A process for the preparation of an agent with the active substance flupirtine to combat muscular tension and the use of flupirtine for such purpose
EP0460912A3 (en) Medicaments for the treatment of sexual disorder
ZA878652B (en) Agents for combating pests and plant treatment agents
IL112029A (en) Raloxifine and related compounds for use as medicaments for the treatment of disorders associated with an excess of tachykinin
EP0331620A3 (en) Agent for the treatment of parkinson's disease
HU9500933D0 (en) Use of il-10 to prevent or treat insulin-dependent diabetes mellitus
MY104521A (en) Treatment of depression.
EP0147707A3 (en) 1,7-diphenyl-3-methylaza-7-cyano-8-methylnonane useful in combating diseases
UA29461C2 (uk) Засіб для лікування амілоїдозу, спосіб лікування амілоїдозу
EP0872246A4 (en) INNOVATIVE MEDICINE TO REDUCE PAIN AND PROMOTE REMOVAL OF CONCRETE IN UROLITHIASIS
GR3029726T3 (en) Use of a therapeutic compound for the treatment of bronchitis
GR3002925T3 (en) Compound active in cardiovascular therapy
ATE72115T1 (de) Anwendung von 1,6-dimethyl-4-oxo-1,6,7,8,9a-
FR2714058B1 (fr) Dérivés de 1,3-dioxane trisubstitués, leur préparation et leur application en thérapeutique.
GEP19971009B (en) Flupirtine in combination with antiparkinsonica against muscle bracing
ZA923505B (en) Treatment of fatigue syndrome
ZA89574B (en) Compounds with a psychotropic action,agents containing them,and the use thereof for the treatment and prophylaxis of disorders of the central nervous system